GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (LTS:0RHR) » Definitions » EV-to-Revenue

Kuros Biosciences (LTS:0RHR) EV-to-Revenue : 15.21 (As of Dec. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Kuros Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kuros Biosciences's enterprise value is CHF799.26 Mil. Kuros Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was CHF52.54 Mil. Therefore, Kuros Biosciences's EV-to-Revenue for today is 15.21.

The historical rank and industry rank for Kuros Biosciences's EV-to-Revenue or its related term are showing as below:

LTS:0RHR' s EV-to-Revenue Range Over the Past 10 Years
Min: -83.23   Med: 6.79   Max: 142.75
Current: 15.21

During the past 13 years, the highest EV-to-Revenue of Kuros Biosciences was 142.75. The lowest was -83.23. And the median was 6.79.

LTS:0RHR's EV-to-Revenue is ranked worse than
87.26% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: 3.405 vs LTS:0RHR: 15.21

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-12), Kuros Biosciences's stock price is CHF20.65. Kuros Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was CHF1.42. Therefore, Kuros Biosciences's PS Ratio for today is 14.53.


Kuros Biosciences EV-to-Revenue Historical Data

The historical data trend for Kuros Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences EV-to-Revenue Chart

Kuros Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.32 9.95 2.65 1.77 3.47

Kuros Biosciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.77 - 3.47 -

Competitive Comparison of Kuros Biosciences's EV-to-Revenue

For the Medical Devices subindustry, Kuros Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's EV-to-Revenue falls into.



Kuros Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Kuros Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=799.262/52.542
=15.21

Kuros Biosciences's current Enterprise Value is CHF799.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was CHF52.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kuros Biosciences  (LTS:0RHR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Kuros Biosciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=20.65/1.421
=14.53

Kuros Biosciences's share price for today is CHF20.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was CHF1.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kuros Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kuros Biosciences Business Description

Traded in Other Exchanges
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences Headlines

No Headlines